Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma
British Journal of Surgery · 2024
DOI: 10.1093/bjs/znae038 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Jun Okui und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Overall survival is considered as one of the most important endpoints of treatment efficacy but often requires long follow-up. This study aimed to determine the validity of recurrence-free survival as a surrogate endpoint for overall survival in patients with surgically resectable advanced oesophageal squamous cell carcinoma (OSCC).
Methods
Patients with OSCC who received neoadjuvant cisplatin and 5-fluorouracil, or docetaxel, cisplatin and 5-fluorouracil, at 58 Japanese oesophageal centres certified by the Japan Esophageal Society were reviewed retrospectively. The correlation between recurrence-free and overall survival was assessed using Kendall's τ.
Results
The study included 3154 patients. The 5-year overall and recurrence-free survival rates were 56.6 and 47.7% respectively. The primary analysis revealed a strong correlation between recurrence-free and overall survival (Kendall's τ 0.797, 95% c.i. 0.782 to 0.812) at the individual level. Subgroup analysis showed a positive relationship between a more favourable pathological response to neoadjuvant chemotherapy and a higher τ value. In the meta-regression model, the adjusted R2 value at the institutional level was 100 (95% c.i. 40.2 to 100)%. The surrogate threshold effect was 0.703.
Conclusion
There was a strong correlation between recurrence-free and overall survival in patients with surgically resectable OSCC who underwent neoadjuvant chemotherapy, and this was more pronounced in patients with a better response to neoadjuvant chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
- Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.
- Biostatistics Unit, Clinical and Translational Research Centre, Keio University Hospital, Tokyo, Japan.
- Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
ORCID-Profile: Jun Okui, Kengo Nagashima, Satoru Matsuda, Akihiko Okamura, Kazuhiro Noma, Hiroshi Miyata
Zitieren
APA
Okui, J., Nagashima, K., Matsuda, S., Sato, Y., Okamura, A., Kawakubo, H., Muto, M., Kakeji, Y., Kono, K., Takeuchi, H., Watanabe, M., Doki, Y., Bamba, T., Fukuda, T., Fujiwara, H., Sato, S., Noma, K., Miyata, H., Fujita, T., & Kitagawa, Y. (2024). Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. British Journal of Surgery. https://doi.org/10.1093/bjs/znae038
Vancouver
Okui J, Nagashima K, Matsuda S, Sato Y, Okamura A, Kawakubo H, et al. Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. British Journal of Surgery. 2024. doi:10.1093/bjs/znae038
BibTeX
@article{Okui2024,
author = {Okui, Jun and Nagashima, Kengo and Matsuda, Satoru and Sato, Yasunori and Okamura, Akihiko and Kawakubo, Hirofumi and Muto, Manabu and Kakeji, Yoshihiro and Kono, Koji and Takeuchi, Hiroya and Watanabe, Masayuki and Doki, Yuichiro and Bamba, Takeo and Fukuda, Takashi and Fujiwara, Hitoshi and Sato, Shinsuke and Noma, Kazuhiro and Miyata, Hiroshi and Fujita, Takeo and Kitagawa, Yuko},
title = {Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma},
journal = {British Journal of Surgery},
year = {2024},
doi = {10.1093/bjs/znae038}
}
EUVIMED